EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access

COVID-19 Vaccination Safety Profiles in Patients With Solid Tumour Cancers: A Systematic Review

S L Shear, K Shams, J Weisberg, N Hamidi, S C Scott

Clinical Oncology · 2023

DOI: 10.1016/j.clon.2023.03.006 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Oncology, 2023. Verfasst von S L Shear und 4 weiteren Autor:innen. Beteiligte Einrichtung: Midwestern University Arizona College of Osteopathic Medicine, Glendale, Arizona, USA. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vaccination has become an essential means of protection for solid tumour patients against coronavirus disease 2019 (COVID-19). In this systematic review, we sought to identify common safety profiles of the COVID-19 vaccine in patients with solid tumours. A search of Web of Science, PubMed, EMBASE and Cochrane was conducted for studies in English full-text that reported side-effect data experienced by patients with cancer who were at least 12 years old with solid tumours or a recent history of solid tumours after receiving either one or multiple doses of the COVID-19 vaccination. Study quality was assessed with the Newcastle Ottawa Scale criteria. Acceptable study types were retrospective and prospective cohorts, retrospective and prospective observational studies, observational analyses and case series; systematic reviews, meta-analyses and case reports were excluded. Among local/injection site symptoms, the most commonly reported were injection site pain and ipsilateral axillary/clavicular lymphadenopathy, whereas the most commonly reported systemic effects were fatigue/malaise, musculoskeletal symptoms and headache. Most side-effects reported were characterised as mild to moderate. A thorough evaluation of the randomised controlled trials for each featured vaccine led to the conclusion that in the USA and abroad, the safety profile seen in patients with solid tumours is comparable with that seen in the general public.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 VaccinesNeoplasmsChildHumansObservational Studies as TopicProspective StudiesRetrospective StudiesSARS-CoV-2Vaccination

Stichwörter der Autor:innen

COVID-19SARS-CoV-2cancersafety profilesolid tumourvaccine

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Midwestern University Arizona College of Osteopathic Medicine, Glendale, Arizona, USA.
  • Midwestern University Arizona College of Osteopathic Medicine, Glendale, Arizona, USA. Electronic address: sscott1@midwestern.edu.

Zitieren

APA

Shear, S. L., Shams, K., Weisberg, J., Hamidi, N., & Scott, S. C. (2023). COVID-19 Vaccination Safety Profiles in Patients With Solid Tumour Cancers: A Systematic Review. Clinical Oncology. https://doi.org/10.1016/j.clon.2023.03.006

Vancouver

Shear SL, Shams K, Weisberg J, Hamidi N, Scott SC. COVID-19 Vaccination Safety Profiles in Patients With Solid Tumour Cancers: A Systematic Review. Clinical Oncology. 2023. doi:10.1016/j.clon.2023.03.006

BibTeX
@article{Shear2023,
  author = {Shear, S L and Shams, K and Weisberg, J and Hamidi, N and Scott, S C},
  title = {COVID-19 Vaccination Safety Profiles in Patients With Solid Tumour Cancers: A Systematic Review},
  journal = {Clinical Oncology},
  year = {2023},
  doi = {10.1016/j.clon.2023.03.006}
}
Kostenlos starten →